Study
| A Phase III placebo-controlled, Randomized, Open-label trial (KEYNOTE-671) |
| Resectable, early stage (stage II and III) NSCLC |
| Arm A: Pembrolizumab + chemotherapyS->Pembrolizumab (n=397) |
| Arm B: ChemtherapyS->PBO (n=400) |
Efficacy
| • mEFS: NR vs 17.0 ms, HR:0.58, p<0.001 |
| 24 mos EFS: 62.4% vs 40.6% |
| mOS: NR vs. 45.5 mos, p=0.02 (NS) |
| 24 mos OS: 80.9% vs. 77.6% |
| mPR: 30.2% vs 11.0%, p<0.001 |
| PcR: 18.1% vs. 4.0%, p=0.0001 |
Safety
| Grade3: Neutropenia (20.7% vs.19%), anemia (7.3% vs. 5.5%) |
NEJM JUN 3, 2023
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
http://doi.org/10.1056/NEJMoa2302983
Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023
